Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
1,248
Views
0
CrossRef citations to date
0
Altmetric
Rapid Communication

Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?

Juan Carlos Olivares-Gazcaa Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;b Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, MéxicoView further author information
,
María de Lourdes Pastelín-Martíneza Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;c Facultad de Medicina, Universidad Anáhuac Puebla, Puebla, MéxicoView further author information
,
Merittzel Abigail Montes-Roblesa Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;c Facultad de Medicina, Universidad Anáhuac Puebla, Puebla, MéxicoView further author information
,
Moisés Manuel Gallardo-Péreza Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;b Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, MéxicoView further author information
,
Edgar J. Hernández-Floresa Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;b Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, MéxicoView further author information
,
Max Robles-Nastaa Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;b Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, MéxicoView further author information
,
Daniela Sánchez-Bonillaa Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;b Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, MéxicoView further author information
,
Guillermo J. Ruiz-Delgadoa Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;b Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, MéxicoCorrespondence[email protected]
View further author information
&
Guillermo J. Ruiz-Argüellesa Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México;b Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, MéxicoORCID Iconhttps://orcid.org/0000-0002-9335-0653View further author information
ORCID Icon show all
Article: 2242176 | Received 23 Jun 2023, Accepted 25 Jul 2023, Published online: 02 Aug 2023

References

  • Ruiz-Argüelles GJ, Ruiz-Delgado GJ, González-Llano O, et al. Haploidentical bone marrow transplantation in 2015 and beyond. Curr Oncol Rep. 2015 Dec;17(12):57. doi:10.1007/s11912-015-0482-9. PMID: 26467275.
  • Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005. PMID: 18489989; PMCID: PMC2633246.
  • Chang Y-J, Ding Q, Hwang WYK, et al. Editorial: recent developments in haploidentical hematopoietic cell transplantation: therapy and complications. Front Immunol. 2021 Aug 17;12:746221. doi:10.3389/fimmu.2021.746221. PMID: 34484249; PMCID: PMC8416152.
  • Murrieta-Álvarez I, Ruiz-Argüelles GJ. Bien plus encore: haplos indeed can be completed on an outpatient basis. Transplant Cell Ther. 2021 Jun;27(6):519–520. doi:10.1016/j.jtct.2021.03.009. Epub 2021 Mar 8. PMID: 33819480.
  • Colunga-Pedraza PR, Gómez-De León A, Rodríguez-Roque CS, et al. Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide Is safe and feasible. Transplant Cell Ther. 2021 Mar;27(3):259.e1–259.e6. doi:10.1016/j.jtct.2020.12.006. Epub 2020 Dec 16. PMID: 33781529.
  • Duléry R, Goudet C, Mannina D, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. 2022 Dec 30;58:386–392. doi:10.1038/s41409-022-01908-y. Epub ahead of print. PMID: 36585459.
  • Nakamae H, Okamura H, Hirose A, et al. A prospective study of an HLA-haploidentical peripheral blood stem cell transplantation regimen based on modification of the dose of posttransplant cyclophosphamide for poor prognosis or refractory hematological malignancies. Cell Transplant. 2022 Jan–Dec;31:096368972211120. doi:10.1177/09636897221112098. PMID: 35906755; PMCID: PMC9340897.
  • Sugita J, Kamimura T, Ishikawa T, et al. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021 Mar;56(3):596–604. doi:10.1038/s41409-020-01065-0. Epub 2020 Sep 24. PMID: 32973350.
  • Wang Y, Wu D-P, Liu Q-F, et al. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019 Sep 3;12(1):88. doi:10.1186/s13045-019-0781-y. PMID: 31481121; PMCID: PMC6724335.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.